Table of Content

iconOpen Access

RETRACTION

crossmark

Retraction: Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial

by Xingbang Li1, Xuan Zheng2, Bowen Jin1, Yunyan Li1, Yongyu Shao1, Xiaoxian Deng1, Dingyang Li1, Shanshan Li1, Hongmei Zhou1, Jie Zhang3, Xianya Zhang4, Qunshan Shen1, Gangcheng Zhang2

1 Congenital Heart Disease Center, Wuhan Asia Heart Hospital, Wuhan University of Science and Technology, Wuhan, 430022, China
2 Structural Heart Disease Center, Zhongnan Hospital, Wuhan University, Wuhan, 430071, China
3 Department of Cardiothoracic and Vascular Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
4 Department of Medical Ultrasound, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China

Congenital Heart Disease 2023, 18(4), 489-489. https://doi.org/10.32604/chd.2023.031413

This article is a retraction of:

Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial
Read original article

Abstract

This article has no abstract.

The published article titled “Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial”, has been retracted from journal Congenital Heart Disease, Vol. 18, No. 3, 2023, pp. 373–385.

DOI: 10.32604/chd.2023.028979

URL: https://www.techscience.com/chd/v18n3/53122/html

The authors declare that due to the following reasons, they have to retract the published article from Congenital Heart Disease:

The retraction has been agreed upon due to the re-assessment of RLS at six months being missing, which would induce significant bias to current conclusions. The authors have made great efforts to recover those data. However, they have yet to be available currently. It would be impossible to add those data in a short time. Current conclusions might mislead the audience, which was not the original purpose of publishing our paper. After careful consideration, the authors require to withdraw their paper.

The Editor-in-Chief of CHD has reviewed and agreed to retract this article from Congenital Heart Disease.


Cite This Article

APA Style
Li, X., Zheng, X., Jin, B., Li, Y., Shao, Y. et al. (2023). Retraction: safety and efficacy of biodegradable patent foramen ovale occluder in patients with migraine: A clinical trial. Congenital Heart Disease, 18(4), 489-489. https://doi.org/10.32604/chd.2023.031413
Vancouver Style
Li X, Zheng X, Jin B, Li Y, Shao Y, Deng X, et al. Retraction: safety and efficacy of biodegradable patent foramen ovale occluder in patients with migraine: A clinical trial. Congeni Heart Dis. 2023;18(4):489-489 https://doi.org/10.32604/chd.2023.031413
IEEE Style
X. Li et al., “Retraction: Safety and Efficacy of Biodegradable Patent Foramen Ovale Occluder in Patients with Migraine: A Clinical Trial,” Congeni. Heart Dis., vol. 18, no. 4, pp. 489-489, 2023. https://doi.org/10.32604/chd.2023.031413


cc Copyright © 2023 The Author(s). Published by Tech Science Press.
This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 752

    View

  • 396

    Download

  • 1

    Like

Share Link